Inclusion Criteria:

          -  Willing and able to provide written informed consent.

          -  Histologically confirmed locally advanced or metastatic urothelial carcinoma or
             histologically confirmed or cytologically confirmed diagnosis of stage IV NSCLC
             lacking epidermal growth factor receptor (EGFR)-sensitizing mutation and/or
             anaplastic lymphoma kinase (ALK) translocation.

          -  Male or female patients, age 18 years or older at the time of signing the informed
             consent form (ICF).

          -  Life expectancy > 12 weeks as determined by the Investigator.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Measurable disease per RECIST 1.1.

          -  Patients must not have received prior immunotherapy with immunomodulators, including
             but not limited to checkpoint inhibitors such as anti PD-1, anti-PD-L1, anti-PD-L2,
             anti CD137, or anti CTLA-4 (cytotoxic T lymphocyte-associated protein 4) antibody, or
             any other antibody or drug specifically targeting T cell co stimulation or checkpoint
             pathways, indoleamine 2,3 dioxydenase pathway inhibitors, cancer vaccines, adoptive
             cell therapies, or other cytokine therapies.

          -  Patients must have received no more than 1 line of platinum-containing chemotherapy
             and have disease progression during or following this therapy, or patient refuses
             standard of care.

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Use of an investigational agent or an investigational device within 28 days before
             administration of first dose of study drug(s).

          -  Females who are pregnant or breastfeeding.

          -  Patients who have an active, known or suspected autoimmune disease. Patients
             requiring systemic treatment within the past 3 months or a documented history of
             clinically severe autoimmune disease that requires systemic steroids or
             immunosuppressive agents. (Exceptions include any patient on 10 mg or less of
             prednisone or equivalent, patients with vitiligo, hypothyroidism stable on hormone
             replacement, Type I diabetes, Graves' disease, Hashimoto's disease, alopecia areata,
             eczema, or with Medical Monitor approval).

          -  History of allergy or hypersensitivity to study drug components.

          -  Active malignancy not related to the current diagnosed malignancy.

          -  History of organ transplant that requires use of immune suppressive agents.

          -  Use of warfarin within 14 days of initiating study drug(s). (Note: Low molecular
             weight heparin is allowed on the study.)

          -  Evidence of clinically significant interstitial lung disease or active, noninfectious
             pneumonitis.

          -  Prior surgery or radiotherapy within 14 days of initiating study drug(s). Patients
             must have recovered from all radiation-related toxicities, not required
             corticosteroids and have not had radiation pneumonitis.

          -  Additional criteria may apply